Endoscopy

Himax Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results; Provides First Quarter 2024 Guidance

Retrieved on: 
Tuesday, February 6, 2024
Well, OLED, EPS, SNR, GM, NB, DB, ADS, Skeleton, Ecosystem, AMOLED, Name, Endoscopy, Software, Engineering, Partnership, CNN, ICS, DSO, Life, Smartphone, CES, CPU, IC, Original equipment manufacturer, Optimism, Movement, Growth, Electronics, Quarter, LCD, Lunar New Year, Tcon, AP, Environment, RGB, Finger, Yoy, Tablet, LED, Microlens, VR, Somatosensory system, Traction, AI, Public expenditure, WLO, CMOS, Vibration, Trust, Depression, System, Video game

TAINAN, Taiwan, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, announced its financial results for the fourth quarter and full year 2023 ended December 31, 2023.

Key Points: 
  • This decline was predominantly driven by the prevailing weak macroeconomic conditions amidst the traditional peak seasonality in the fourth quarter.
  • Meanwhile, Himax’s industry leading, cutting-edge automotive LTDI product started mass production for Geely Auto’s NEVs in the third quarter of 2023.
  • For tablet, Q4 sales grew high teens sequentially, exceeding guidance, driven by successful new product launches by customers during the quarter.
  • Fourth quarter revenues from its non-driver business also exceeded guidance with revenue of $31.0 million but declined 8.2% from a quarter ago.

BariaTek Medical Announces the First-in-Human Implantation of Its BariTon™ Device, a Non-Surgical Gastro-Intestinal Medical Device Aiming to Replicate the Efficacy of Obesity Surgery Without the Invasiveness

Retrieved on: 
Tuesday, February 6, 2024
Medical Devices, Health, Diabetes, Surgery, Health Technology, Clinical Trials, Surgeon, Life expectancy, Endoscopy, Obesity, Prescription, Clinical trial, Patient, Prevalence, Safety, Bariatric surgery, Mouth, Gastroenterology, Cancer, Anatomy, Medical device

Obesity is a chronic and debilitating disease affecting more than one billion people worldwide.

Key Points: 
  • Obesity is a chronic and debilitating disease affecting more than one billion people worldwide.
  • It bears a tremendous economic burden to healthcare systems surpassing that of cardiovascular diseases and cancer and its prevalence is increasing worldwide.
  • It often leads to diabetes, high blood pressure, heart disease and reduced life expectancy.
  • We are thrilled about the prospect of bringing our highly differentiated solution, the BariTon™, to obesity gastroenterologists and surgeons and to patients worldwide.

First Patient Enrollment into Aspero Medical NIH-Funded Study

Retrieved on: 
Monday, February 5, 2024
Pillar, Randomized controlled trial, MD, NIH, Diagnosis, FDA, RCT, National Institutes of Health, Food, SBIR, Endoscopy, Bangladesh Technical Education Board, Medical device

The study will be specific to the middle third of small bowel for balloon enteroscopy and completion is expected by end of 2024.

Key Points: 
  • The study will be specific to the middle third of small bowel for balloon enteroscopy and completion is expected by end of 2024.
  • The first patient of this study was enrolled last week.
  • Unlike the Ancora-SB balloon made by Aspero Medical, current balloons are smooth and round making them prone to slippage.
  • “We are beyond excited to have the first patient enrolled in the NIH-funded RCT.

Electronic adhesives by Meridian EPO-TEK® highlighted at MD&M West

Retrieved on: 
Monday, February 5, 2024
Ultrasound, Electronics, CGMS, UV, MD, PZT, MED, ISO, Temperature, Commercial, Catheter, Anaheim Convention Center, Endoscopy, PCB, Medical device

CHARLOTTE, N.C., Feb. 5, 2024 /PRNewswire-PRWeb/ -- Meridian Adhesives Group (Meridian) will feature EPO-TEK®'s advanced adhesive solutions for medical electronic applications at booth 531 at the MD&M West Show from Feb. 6-8 at the Anaheim Convention Center.

Key Points: 
  • Meridian Adhesives Group (Meridian) will feature EPO-TEK®'s advanced adhesive solutions for medical electronic applications at booth 531 at the MD&M West Show from Feb. 6-8 at the Anaheim Convention Center
    CHARLOTTE, N.C., Feb. 5, 2024 /PRNewswire-PRWeb/ -- Meridian Adhesives Group (Meridian) will feature EPO-TEK®'s advanced adhesive solutions for medical electronic applications at booth 531 at the MD&M West Show from Feb. 6-8 at the Anaheim Convention Center.
  • The company's biocompatible/medical device grade adhesives are available in room temperature two-part systems or pre-mixed frozen single-component syringes.
  • Meridian will also highlight the EPO-TEK® "MED" line, which includes EPO-TEK® Biocompatible Medical Device Grade Products.
  • As a global manufacturer and custom formulator specializing in epoxy and UV adhesives, its focus is on medical device applications.

United States Ambulatory Surgery Center Market Report 2023: Comprehensive Insights Reveal Surge in Hybrid ASC/OBL Models and Technological Innovations - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 31, 2024
Surgery, Health, Cardiology, Intelligence, Growth, EHR, RFID, Endoscopy, Research, Ophthalmology, OBL, CON, Policy, Abdominal ultrasonography, Elective surgery, ASC, Medicare, Nursing

The "2023 United States Ambulatory Surgery Center Market Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2023 United States Ambulatory Surgery Center Market Report" report has been added to ResearchAndMarkets.com's offering.
  • The in-depth analysis provides invaluable data for 2023, reflecting on the market's valuation, which currently stands at a robust $43.1 billion.
  • Hybrid ASC/OBL Surge: A rising trend is observed with hybrid ASC/Office-Based Lab (OBL) models, especially in cardiology procedures, given their cost-efficiency and operational flexibility.
  • For those looking to gain a comprehensive understanding of the ASC market, this research publication serves as an essential resource.

Leading Journal Unveils Groundbreaking Efficacy of Novel Treatment for Obesity, Diabetes, and Liver Disease

Retrieved on: 
Thursday, January 18, 2024
Obesity, DSM-IV codes, Patient, Weight gain, Overalls, MASH, Bypass surgery, Insulin, Safety, King's College London, Glucose, Liver, BMI, Stomach, Gastroenterology, Endoscopy, Medical device

The study, authored by an international team of prominent researchers, appeared in Gut, which is the leading international journal in the field of gastroenterology.

Key Points: 
  • The study, authored by an international team of prominent researchers, appeared in Gut, which is the leading international journal in the field of gastroenterology.
  • Substantial improvements in how the body handles insulin and reduces glucose in the liver compared to controls.
  • Markedly improved response to insulin, enhanced overall body’s use of glucose, and beneficial changes in metabolic health-related gut bacteria.
  • Should the upcoming trials, as anticipated, confirm the safety and efficacy demonstrated in animal studies, this device is poised to transform the treatment of severe and morbid obesity in the years ahead.

Integrated Endoscopy Partners with Frii Medical to Market Wireless, Single-Use Shaver System

Retrieved on: 
Wednesday, January 24, 2024
Science, Research, Surgery, General Health, Health, Medical Devices, Hospitals, Other Health, Family, Arthroscopy, Cannula, Sterilization, Partnership, American Academy, Sharp, AAOS, FDA, Integration, Surgeon, Endoscopy, CE, Medical device

Integrated Endoscopy, a medical device company pioneering the development of cordless 4K, low-cost, single-use endoscopes for the arthroscopic surgery market, has announced its partnership with Frii Medical to bring its proprietary single-use shaver system to the global market.

Key Points: 
  • Integrated Endoscopy, a medical device company pioneering the development of cordless 4K, low-cost, single-use endoscopes for the arthroscopic surgery market, has announced its partnership with Frii Medical to bring its proprietary single-use shaver system to the global market.
  • The first-of-its-kind wireless shaver offers surgeons and health centers the freedom to operate efficiently in any operating room setting, eliminating power cords to the controller.
  • The system comes with a reusable motor / battery module and the associated recharger station.
  • Like Integrated Endoscopy’s NUVIS single-use arthroscope, Frii’s single-use battery shaver system eliminates the costs of processing and sterilization, ensuring quality and performance every time and significantly reducing the cost of capital equipment required with traditional shaver systems.

The Inner Circle Acknowledges, Hank C. Hill as a Pinnacle Life Member

Retrieved on: 
Monday, January 29, 2024
Surgical oncology, Philosophy, Neoplasm, Patient, Annals of Surgical Oncology, Research, Endocrine system, Sarcoma, Radiation, ABS, General surgery, Mentorship, Dance, Health, Multimedia, Knowledge, Music, Inner circle, Surgeon, National Research Service Award, Society, University, MD Anderson Cancer Center, Cancer, Skin, Gastrointestinal tract, Harlem Hospital Center, Esophagus, NIH, Liver, Stomach, Rectum, T-32, Morehouse School of Medicine, Breast, Tennis, Education, Publication, Pancreas, Endoscopy, Nursing

BROOKSVILLE, Fla., Jan. 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hank C. Hill is acknowledged as a Pinnacle Life Member for his contributions to the field of Surgical Oncology.

Key Points: 
  • BROOKSVILLE, Fla., Jan. 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hank C. Hill is acknowledged as a Pinnacle Life Member for his contributions to the field of Surgical Oncology.
  • Dr. Hill pursued higher education at the Brooklyn Campus of Long Island University where he earned his Bachelor of Science degree in Biology/Pre-Med.
  • Anderson Cancer Center in Houston, where he earned a surgical oncology research fellowship certificate in tumor biology.
  • Aside from his professional pursuits, Dr. Hill enjoys traveling, dancing (soca, reggae, reggaeton, R&B), and listening to music.

Mirai Medical Welcomes Former Boston Scientific Executive, David A. Pierce, as Non-Executive Director

Retrieved on: 
Tuesday, January 23, 2024
Biotechnology, General Health, Medical Devices, Other Health, Health, Gastrointestinal tract, Medtech, Medicine, Nursing credentials and certifications, Boston Scientific, Gastrointestinal Endoscopy, Doctor of Philosophy, Endoscopy, Diagnosis, PFA, Growth, Management

Mirai Medical, a cutting-edge medical technology start-up and leader in Pulsed Field Ablation (PFA) within the Gastrointestinal Tract, proudly welcomes David A.

Key Points: 
  • Mirai Medical, a cutting-edge medical technology start-up and leader in Pulsed Field Ablation (PFA) within the Gastrointestinal Tract, proudly welcomes David A.
  • Pierce's distinguished career at Boston Scientific, spanning 31 years, has been marked by numerous accomplishments and a deep understanding of the MedTech landscape.
  • His extensive experience at Boston Scientific, coupled with his deep knowledge of the industry, will undoubtedly play a pivotal role in guiding Mirai Medical's strategic direction,” said Mirai Medical CEO, Dr. Declan Soden, PhD.
  • Pierce shared his enthusiasm for joining Mirai Medical, saying, “I am honoured to be part of Mirai Medical, a company at the forefront of innovation in interventional endoscopy.

World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss

Retrieved on: 
Tuesday, January 23, 2024
Health, Health Technology, Other Health, Fitness & Nutrition, Managed Care, General Health, Biotechnology, Obesity, Bed, Physiology, Patient, Musgrove Park Hospital, Injection, Somerset NHS Foundation Trust, Professor, Weight loss, Body mass index, Partnership, Bariatric surgery, Gastric balloon, Quality of life, Human, BMI, Stomach, Endoscopy, NHS, Health insurance

It is proven to help patients lose an average of 10-15% of their body weight after approximately four months2.

Key Points: 
  • It is proven to help patients lose an average of 10-15% of their body weight after approximately four months2.
  • Studies show that on average, 96% of weight loss can be sustained 1 year after the balloon passes3.
  • The first two patients to receive the treatment were treated at Somerset NHS Foundation Trust’s (FT) Musgrove Park Hospital in November, under the care of Professor Richard Welbourn, consultant bariatric surgeon at Somerset NHS Foundation Trust.
  • “People with severe obesity are prone to diseases, such as type 2 diabetes, which can be reversed with weight loss.